StockData
Alnylam Pharmaceuticals, Inc. logo

Alnylam Pharmaceuticals, Inc. (ALNY) shareholders

ALNYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3047% below fair value
$156.50−3.23 (-2.02%)

Close on Nov 17, 2026Market cap $20.96BP/E 8.1Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
99.7%
133M of 134M shares
Institutional holders
788
87 new, 80 sold out
Net institutional buying
2M
In Q2 2026
Insider trades, 12 months
2 buys · 248 sales
Net sold $26.31M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
FMR LLC
Joint filing with Abigail P. Johnson (12.80%)
16,834,09512.80%13G (passive) amendmentSep 30, 2025
Abigail P. Johnson
Joint filing with FMR LLC (9.50%)
12,675,0539.50%13G (passive) amendmentSep 30, 2026
Capital World Investors10,916,7998.20%13G (passive) amendmentMar 31, 2026
Capital Research Global Investors9,471,1817.10%13G (passive) amendmentMar 31, 2026
BlackRock, Inc.8,546,5576.80%13G (passive) amendmentDec 31, 2023
Vanguard Capital Management7,104,5365.35%13G (passive)Mar 31, 2026
Vanguard Portfolio Management6,732,0825.03%13G (passive)Sep 30, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of ALNYValueChange% of portfolio
FMR LLC15,023,96211.22%$4.52B+444,7960.20%
Capital World Investors11,144,8468.32%$3.35B+342,4980.40%
BlackRock, Inc.10,907,6758.14%$3.28B+462,7670.05%
Capital Research Global Investors9,750,6997.28%$2.94B+279,5180.41%
Vanguard Portfolio Management LLC6,538,3904.88%$1.97B+47,1100.09%
Vanguard Capital Management LLC6,029,4784.50%$1.82B+82,7720.04%
T. Rowe Price Investment Management, Inc.5,642,1734.21%$1.70B+448,8491.11%
Invesco Ltd.3,754,3182.80%$1.13B−320,8020.09%
State Street Corp3,555,6892.65%$1.07B+232,9910.03%
JPMorgan Chase & Co2,675,5172.00%$785.32M−3,648,2350.04%
Geode Capital Management, LLC2,635,8401.97%$791.35M−24,5450.04%
Baillie Gifford & Co2,439,8891.82%$734.48M−53,9770.67%
Norges Bank2,271,8131.70%$683.88MNew0.07%
Wellington Management Group Llp2,110,4071.58%$635.30M+174,4820.11%
Orbis Allan Gray Ltd1,987,4071.48%$598.27M+652,5822.06%
Dodge & Cox1,955,3931.46%$588.63M+26,1400.31%
Two Sigma Investments, LP1,875,9371.40%$564.71M−116,6400.41%
American Century Companies Inc1,853,9561.38%$558.10M+51,5930.25%
Clearbridge Investments, LLC1,259,4830.94%$379.14M−96,5530.31%
Price T Rowe Associates Inc /Md/1,149,2010.86%$345.95M−283,5470.03%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026788133M99.7%87 / 324280 / 8012M9M
Q1 2026793131M98.1%106 / 320261 / 15630M19M
Q4 2025852134M100.0%172 / 289292 / 11715M15M
Q3 2025823134M100.0%225 / 283223 / 4920M18M
Q2 2025654133M99.0%98 / 261216 / 6310M7M
Q1 2025625129M96.7%106 / 235205 / 6710M8M
Q4 2024594128M95.5%98 / 239180 / 6213M11M
Q3 2024568126M94.1%107 / 221171 / 5722M9M
Q2 2024523122M90.9%88 / 193168 / 5712M8M
Q1 2024498118M88.0%71 / 205150 / 6410M13M
Q4 2023499121M90.4%96 / 168159 / 449M6M
Q3 2023453118M88.0%43 / 161166 / 595M5M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

705 funds held ALNY in Q2 2026, 28% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of ALNYValue% of fundAs of
Growth Fund of America7,670,9945.73%$2.32B0.64%May 31, 2026
Vanguard Total Stock Market Index Fund4,239,0873.16%$1.28B0.06%Jun 30, 2026
AMCAP Fund4,101,6803.06%$1.24B1.27%May 31, 2026
Vanguard Mid-Cap Index Fund2,893,0302.16%$870.89M0.39%Jun 30, 2026
Invesco QQQ Trust, Series 12,834,0952.12%$853.15M0.17%Jun 30, 2026
Fidelity OTC Portfolio2,140,8241.60%$439.98M1.02%Jul 31, 2026
Vanguard Health Care Fund2,136,5801.60%$439.11M1.15%Jul 31, 2026
T. Rowe Price Capital Appreciation Fund2,034,7611.52%$612.52M0.87%Jun 30, 2026
Vanguard Growth Index Fund1,624,0011.21%$488.87M0.13%Jun 30, 2026
Investment Co of America1,612,9421.20%$485.54M0.26%Jun 30, 2026
Vanguard Extended Market Index Fund1,530,8651.14%$460.84M0.47%Jun 30, 2026
Fidelity Growth Company Fund1,338,8741.00%$404.31M0.41%May 31, 2026
Dodge & Cox Stock Fund1,233,2000.92%$371.23M0.31%Jun 30, 2026
Growth Fund1,197,8760.89%$360.60M0.63%Jun 30, 2026
T. Rowe Price Mid-Cap Growth Fund, Inc.1,165,7730.87%$350.93M1.52%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Yvonne GreenstreetChief Executive Officer, Director85,2090.06%Nov 17, 2026
Bryan SupranEVP, CLO and Secretary12,8070.01%Oct 6, 2026
Melissa McLaughlinChief Human Resources Officer11,6730.01%Apr 7, 2026
Kevin Joseph FitzgeraldCSO & EVP, Head of Research21,1060.02%Mar 6, 2026
Jeffrey V. PoultonEVP, Chief Financial Officer63,1940.05%Mar 6, 2026
Tolga TangulerEVP, Chief Commercial Officer34,2970.03%Mar 6, 2026
Pushkal GargEVP Chief R&D21,1240.02%Mar 6, 2026
Robert W. HessleinEVP, CLO and Secretary8,0020.01%Mar 5, 2025
David E. I. PyottDirector33,2620.02%Nov 12, 2026
Charles Elliott SigalDirector5,0460.00%Nov 12, 2026
Amy W. SchulmanDirector25,9590.02%Nov 12, 2026
Benjamin CravattDirector––Jun 3, 2026
Colleen F. ReitanDirector1,4460.00%May 22, 2026
Peter N. KelloggDirector1,4460.00%May 22, 2026
Margaret A. HamburgDirector1,5820.00%May 22, 2026
Olivier BrandicourtDirector1,4460.00%May 22, 2026
Stuart A. ArbuckleDirector6710.00%May 22, 2026
Dennis A. AusielloDirector5,0820.00%May 22, 2026
Michael W. BonneyDirector32,0540.02%Aug 19, 2025
Carolyn R. BertozziDirector7750.00%May 12, 2025
Phillip A. SharpDirector278,1490.21%Jan 24, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Yvonne Greenstreet
Chief Executive Officer, Director
Nov 13, 2026Gift−11,000––84,802
David E. I. Pyott
Director
Nov 10, 2026Option exercise+3,780$71.99$272.12K5,362
Charles Elliott Sigal
Director
Nov 10, 2026Buy+1,600$152.25$243.60K3,600
Amy W. Schulman
Director
Nov 9, 2026Buy+1,910$156.82$299.53K25,959
Bryan Supran
EVP, CLO and Secretary
Oct 2, 2026Sale−1,758$226.88$398.86K12,807
Yvonne Greenstreet
Chief Executive Officer, Director
Sep 19, 2026Award+107––95,802
David E. I. Pyott
Director
Jun 1, 2026Sale(10b5-1 plan)−1,222$299.87$366.44K2,094
David E. I. Pyott
Director
Jun 1, 2026Option exercise+3,830––5,412
David E. I. Pyott
Director
Jun 1, 2026Sale(10b5-1 plan)−495$300.72$148.86K1,599
David E. I. Pyott
Director
Jun 1, 2026Sale(10b5-1 plan)−921$297.71$274.19K4,491
David E. I. Pyott
Director
Jun 1, 2026Sale(10b5-1 plan)−17$302.65$5.15K1,582
David E. I. Pyott
Director
Jun 1, 2026Sale(10b5-1 plan)−1,175$298.91$351.22K3,316
David E. I. Pyott
Director
May 20, 2026Award+671––1,582
Dennis A. Ausiello
Director
May 20, 2026Award+671––1,582
Charles Elliott Sigal
Director
May 20, 2026Award+671––1,446
Peter N. Kellogg
Director
May 20, 2026Award+671––1,446
Colleen F. Reitan
Director
May 20, 2026Award+671––1,446
Olivier Brandicourt
Director
May 20, 2026Award+671––1,446
Amy W. Schulman
Director
May 20, 2026Award+838––24,049
Stuart A. Arbuckle
Director
May 20, 2026Award+671––671
Margaret A. Hamburg
Director
May 20, 2026Award+671––1,582
Amy W. Schulman
Director
May 13, 2026Option exercise+11,250$70.20$789.75K23,211
Melissa McLaughlin
Chief Human Resources Officer
Apr 6, 2026Sale(10b5-1 plan)−56$320.14$17.93K11,673
Melissa McLaughlin
Chief Human Resources Officer
Apr 6, 2026Sale(10b5-1 plan)−909$329.76$299.75K10,764
Melissa McLaughlin
Chief Human Resources Officer
Apr 6, 2026Sale(10b5-1 plan)−829$330.46$273.95K9,935
Melissa McLaughlin
Chief Human Resources Officer
Apr 6, 2026Sale(10b5-1 plan)−293$331.89$97.24K9,642
Melissa McLaughlin
Chief Human Resources Officer
Apr 6, 2026Sale(10b5-1 plan)−199$333.94$66.45K9,443
Melissa McLaughlin
Chief Human Resources Officer
Apr 2, 2026Sale(10b5-1 plan)−147$320.62$47.13K12,287
Melissa McLaughlin
Chief Human Resources Officer
Apr 2, 2026Sale(10b5-1 plan)−245$322.86$79.10K11,818
Melissa McLaughlin
Chief Human Resources Officer
Apr 2, 2026Sale(10b5-1 plan)−224$321.64$72.05K12,063
Melissa McLaughlin
Chief Human Resources Officer
Apr 2, 2026Sale(10b5-1 plan)−86$319.69$27.49K12,434
Melissa McLaughlin
Chief Human Resources Officer
Apr 2, 2026Sale(10b5-1 plan)−81$323.64$26.21K11,737
Melissa McLaughlin
Chief Human Resources Officer
Apr 2, 2026Sale(10b5-1 plan)−8$325.49$2.60K11,729
Melissa McLaughlin
Chief Human Resources Officer
Apr 2, 2026Sale(10b5-1 plan)−359$317.44$113.96K12,729
Melissa McLaughlin
Chief Human Resources Officer
Apr 2, 2026Sale(10b5-1 plan)−265$316.61$83.90K13,088
Melissa McLaughlin
Chief Human Resources Officer
Apr 2, 2026Sale(10b5-1 plan)−209$318.47$66.56K12,520
Kevin Joseph Fitzgerald
CSO & EVP, Head of Research
Mar 5, 2026Sale(10b5-1 plan)−153$326.24$49.91K20,569
Kevin Joseph Fitzgerald
CSO & EVP, Head of Research
Mar 5, 2026Sale(10b5-1 plan)−148$324.60$48.04K20,722
Kevin Joseph Fitzgerald
CSO & EVP, Head of Research
Mar 5, 2026Sale(10b5-1 plan)−233$323.25$75.32K20,870
Kevin Joseph Fitzgerald
CSO & EVP, Head of Research
Mar 5, 2026Sale(10b5-1 plan)−124$321.81$39.90K21,103
Pushkal Garg
EVP Chief R&D
Mar 5, 2026Sale(10b5-1 plan)−654$322.33$210.80K20,443
Pushkal Garg
EVP Chief R&D
Mar 5, 2026Sale(10b5-1 plan)−740$323.55$239.43K19,703
Pushkal Garg
EVP Chief R&D
Mar 5, 2026Sale(10b5-1 plan)−510$324.59$165.54K19,193
Pushkal Garg
EVP Chief R&D
Mar 5, 2026Sale(10b5-1 plan)−500$326.08$163.04K18,693
Kevin Joseph Fitzgerald
CSO & EVP, Head of Research
Mar 4, 2026Sale(10b5-1 plan)−59$320.81$18.93K21,744
Kevin Joseph Fitzgerald
CSO & EVP, Head of Research
Mar 4, 2026Sale(10b5-1 plan)−79$321.82$25.42K21,665
Kevin Joseph Fitzgerald
CSO & EVP, Head of Research
Mar 4, 2026Sale(10b5-1 plan)−28$320.01$8.96K21,803
Kevin Joseph Fitzgerald
CSO & EVP, Head of Research
Mar 4, 2026Sale(10b5-1 plan)−57$325.67$18.56K21,227
Kevin Joseph Fitzgerald
CSO & EVP, Head of Research
Mar 4, 2026Sale(10b5-1 plan)−75$324.88$24.37K21,284
Kevin Joseph Fitzgerald
CSO & EVP, Head of Research
Mar 4, 2026Sale(10b5-1 plan)−210$323.84$68.01K21,359
Kevin Joseph Fitzgerald
CSO & EVP, Head of Research
Mar 4, 2026Sale(10b5-1 plan)−96$323.01$31.01K21,569
Kevin Joseph Fitzgerald
CSO & EVP, Head of Research
Mar 4, 2026Sale(10b5-1 plan)−29$319.03$9.25K21,831
Jeffrey V. Poulton
EVP, Chief Financial Officer
Mar 4, 2026Sale−374$323.01$120.81K63,137
Jeffrey V. Poulton
EVP, Chief Financial Officer
Mar 4, 2026Sale−309$321.82$99.44K63,511
Jeffrey V. Poulton
EVP, Chief Financial Officer
Mar 4, 2026Sale−230$320.81$73.79K63,820
Jeffrey V. Poulton
EVP, Chief Financial Officer
Mar 4, 2026Sale−291$324.88$94.54K62,028
Jeffrey V. Poulton
EVP, Chief Financial Officer
Mar 4, 2026Sale−818$323.84$264.90K62,319
Jeffrey V. Poulton
EVP, Chief Financial Officer
Mar 4, 2026Sale−223$325.67$72.62K61,805
Jeffrey V. Poulton
EVP, Chief Financial Officer
Mar 4, 2026Sale−109$320.01$34.88K64,050
Jeffrey V. Poulton
EVP, Chief Financial Officer
Mar 4, 2026Sale−114$319.03$36.37K64,159

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
4.10%
5M shares short
Days to cover
1.9
At 3M shares a day
Change since last report
-16.8%
From 7M shares
Short volume, 20 days
23.1%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Alnylam Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 1,379 shares on Sep 22, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Bryan Supran
Officer
Oct 2, 20261,758$398.86KOct 2, 2026Restricted Stock Vesting
David E. I. Pyott
Director
Jun 1, 20263,830$1.15MJun 1, 2026Exercise of stock options
Melissa McLaughlin
Officer
Apr 6, 20262,286$731.75KApr 6, 2026Stock Award
Pushkal Garg
Officer
Mar 5, 20262,404$778.15KMar 5, 2026RSU
Kevin Joseph Fitzgerald
Officer
Mar 5, 2026658$212.99KMar 5, 2026RSU
Kevin Joseph Fitzgerald
Officer
Mar 3, 20261,652$530.90KMar 3, 2026RSU
Pushkal Garg
Officer
Mar 3, 20261,775$570.43KMar 3, 2026RSU
Pushkal Garg
Officer
Feb 27, 20264,627$1.53MFeb 27, 2026PSU
Kevin Joseph Fitzgerald
Officer
Feb 17, 20262,041$677.53KFeb 17, 2026PSU
Kevin Joseph Fitzgerald
Officer
Jan 13, 20262,290$845.24KJan 13, 2026PSU
Kevin Joseph Fitzgerald
Officer
Nov 17, 202512,128$5.45MNov 17, 2025Exercise of stock options
Yvonne Greenstreet
Officer, Director
Nov 12, 202525,650$11.62MNov 12, 2025Exercise of stock options
Pushkal Garg
Officer
Oct 3, 20253,022$1.36MOct 3, 2025PSU
Colleen F. Reitan
Director
Sep 9, 202518,000$8.30MSep 9, 2025Exercise of stock options
Tolga Tanguler
Officer
Aug 29, 20253,474$1.57MAug 29, 2025PSU

Congress trades

13 trades in Alnylam Pharmaceuticals reported by 5 members of the House

MemberTypeTradedAmountFiled
Jefferson Shreve
IN06
SoldMay 12, 2025$15K–50KJun 22, 2025
Josh Gottheimer
NJ05 · joint account
SoldJan 29, 2024$1K–15KFeb 15, 2024
Josh Gottheimer
NJ05 · joint account
BoughtJan 11, 2024$1K–15KFeb 15, 2024
Josh Gottheimer
NJ05 · joint account
SoldDec 11, 2023$1K–15KJan 7, 2024
Daniel Goldman
NY10
BoughtMar 6, 2023$15K–50KApr 17, 2023
Daniel Goldman
NY10
SoldJan 31, 2023$15KFeb 24, 2023
Josh Gottheimer
NJ05 · joint account
BoughtSep 28, 2022$1K–15KOct 16, 2022
Barbara J Honorable Comstock
VA10
SoldMar 5, 2018$15K–50KMar 19, 2018
Barbara J Honorable Comstock
VA10
BoughtOct 12, 2017$15K–50KOct 13, 2017
Richard L. Hanna
NY22
BoughtDec 30, 2016$50K–100KJan 18, 2017
Richard L. Hanna
NY22
SoldDec 30, 2016$1K–15KJan 18, 2017
Richard L. Hanna
NY22
SoldDec 13, 2016$100K–250KJan 18, 2017
Richard L. Hanna
NY22
BoughtOct 13, 2016$100K–250KNov 27, 2016

See a number that looks wrong?